Novo presented Phase 3 data showing its weight management candidate CagriSema achieved greater weight loss than Eli Lilly’s tirzepatide, as it outlined its 2030 ambitions at a Capital Markets Day in London, including more than five multi-blockbuster launches by 2030 and more than DKK 150 billion in risk-adjusted pipeline sales in 2035.

The European Medicines Agency’s human medicines committee (CHMP) has adopted a positive opinion recommending marketing authorisation for Novo Nordisk’s Frehemgo (denecimig) for haemophilia A, with or without inhibitors, in adults and children. The company says it is the first factor VIIIa mimetic offering once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen.

The US Food and Drug Administration (FDA) has accepted and granted Priority Review to Alexion, AstraZeneca’s Rare Disease unit, for efzimfotase alfa as a treatment for patients with hypophosphatasia (HPP) aged 2 years and older.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named ‘Mölnlycke Surgical’, while Wound Care and Antiseptics continue as Mölnlycke.

RaySearch Laboratories and US-based Accuray have entered a definitive agreement to expand their collaboration on online adaptive radiation therapy, with Accuray committing to purchase RayStation software licences worth USD 8 million.

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company’s continued market expansion.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Pepaxti (melflufen) be extended to earlier lines of multiple myeloma treatment, a move that would significantly widen the drug’s eligible patient population.

BioArctic’s partner Eisai has received Japanese approval for Leqembi Pen, a subcutaneous autoinjector formulation of the Alzheimer’s drug Leqembi (lecanemab), making Japan the third country globally to approve the self-administered formulation.

Circio Holding has completed a private placement raising approximately NOK 200 million in gross proceeds, earmarked to accelerate a new in vivo CAR-T cell therapy programme built on the company’s circVec circular-RNA platform.

A large population study using NADMED’s redox metabolite testing platform has established healthy reference ranges for NAD and glutathione, two key drivers of cellular energy metabolism, and identified distinct disease-related alterations in both from a single blood sample.

Researchers at the University of Gothenburg have developed a treatment for acute myeloid leukemia that forces cancer cells to run at full throttle while cutting off their energy supply, driving them to burn out and die from the stress. The first study in mice shows highly promising results.

Ada Yonath, the 2009 Nobel laureate in Chemistry, died on August 31, 2026, at the age of 87. She was one of the first Nobel Prize laureates I interviewed as a new editor at Nordic Life Science – and the first I met in person, over an interview at the Grand Hotel in Stockholm. Yonath, who in 2009 became the first woman in 45 years to win the Nobel Prize in Chemistry, spoke to me about her curiosity, polar bears, extremely durable bacteria from the Black Sea, and her passion for science.